trending Market Intelligence /marketintelligence/en/news-insights/trending/ovxe7ui2xekn_vd-51waxg2 content esgSubNav
In This List

Vertex Pharmaceuticals chief medical officer to retire; replacement named

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Vertex Pharmaceuticals chief medical officer to retire; replacement named

Vertex Pharmaceuticals Inc. said Jeffrey Chodakewitz, chief medical officer and executive vice president of global medicines development and medical affairs, will retire from his positions.

Chodakewitz, who joined Vertex in 2014, will remain with the Boston, Mass.-based company as a senior adviser through early 2019.

The developer of serious disease therapies named Reshma Kewalramani as chief medical officer and executive vice president of global medicines development and medical affairs, effective April 1.

Kewalramani serves as senior vice president of clinical development and medical affairs at Vertex.